News

Kadmon has also licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market. Under the

In Europe, there are approximately 12,000 people with CF ages 12 and older who have two copies of this mutation. Vertex will now begin the country-by-country reimbursement approval

The company admitted that it gave rebates and patient referrals to specialty pharmacies for recommending both the drugs. Exjade is used to treat excess iron in blood, while

Invokamet XR is a once-daily fixed-dose combination of canagliflozin and metformin hydrochloride extended release (XR) in two tablets for glycemic control in type 2 diabetics. The FDA approved

BAX 826 is an investigational, extended half-life recombinant Factor VIII (rFVIII) candidate based on the full length ADVATE [Antihemophilic Factor (Recombinant)] molecule. Baxalta plans to enroll 30 patients

The addition of C-103 provides a novel weight loss pharmaceutical product to the M Pharma pipeline. Indicative terms of the letter of intent include an up-front cash payment,

The Company received approval from the U.S. Food and Drug Administration (FDA) of its investigational new drug (IND) application to begin the phase 2 clinical study in September.

Spring Bank chief medical officer Nezam Afdhal said: "Although medications like Viread® are excellent at suppressing HBV replication, ‘HBV cure’ has remained elusive. We are very excited to

BHV-0223 is a unique formulation of a glutamate modulating agent that utilizes the Zydis® ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate